Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose 90Y-hLL2 Radioimmunotherapy with PBSC Rescue in B-Cell Malignancies
NCT00004107Phase 2Completed
- Sponsor
- Garden State Cancer Center
- Start
- Feb 1998
- Primary completion
- May 2001
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 90Y-epratuzumab tetraxetan in Non-Hodgkin lymphoma (NHL), Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL) and 1 more, sponsored by Garden State Cancer Center. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicity. Started Feb 1998; status: completed.
02
Drugs
90Y-epratuzumab tetraxetan
03
Conditions
Non-Hodgkin lymphoma (NHL)Waldenström macroglobulinemia (WM)chronic lymphocytic leukemia (CLL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00004107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004107.